A recent deal struck between Johnson & Johnson and the Global Drug Facility promises improved access to bedaquiline in a number of low income countries, but fails to address structural problems

A century after the discovery of insulin, quality-assured access remains hindered by high prices. The WHO resolution for transparency in pricing of insulin aims at dealing with Big Pharma market monopoly

Nandita Venkatesan and her co-petitioner from South Africa, Phumeza Tisile, are challenging a further extension of the patent that Johnson & Johnson has applied for the salt form of the drug, bedaquline that could be of vital importance in treating drug-resistant TB